Xarelto’s firm top position and Eliquis’s first 2nd in ranking

Published: 2016-09-05 15:52:55

Updated: 2016-09-05 15:52:55

The launch of a next-generation novel oral anticoagulant(NOAC) ‘Eliquis(generic name: apixaban)’ attracted attention of the industry as becoming the top 2 prescription product for the first time in the quarter. ‘Xarelto(generic name: rivaroxaban)’ firmly kept its top position.

According to data of IMS Health, Eliquis was aggregated to took over the top 2^nd prescription position among other NOA...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.